NCT02422615 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 484
- group Id
- BG001
- value
- 242
- group Id
- BG002
- value
- 726
- units
- Participants
- groups
- description
- Ribociclib was administered orally at a daily dose of 600mg for 21 consecutive days within a 28-day cycle. This treatment was combined with fulvestrant, which was administered via intramuscular injections of 500mg every 28 days starting on Day 1 of each cycle. Additionally, an extra dose of fulvestrant was given on Day 15 of Cycle 1.
- id
- BG000
- title
- Ribociclib + Fulvestrant
- description
- Placebo was administered orally for 21 consecutive days within a 28-day cycle. This treatment was combined with fulvestrant, which was administered via intramuscular injections of 500mg every 28 days starting on Day 1 of each cycle. Additionally, an extra dose of fulvestrant was given on Day 15 of Cycle 1. Participants were unblinded after the implementation of protocol amendment 4 (29-Jan-20) and were given the option to crossover to treatment with ribociclib and fulvestrant.
- id
- BG001
- title
- Placebo + Fulvestrant
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.78
- value
- 63.4
- group Id
- BG001
- spread
- 10.59
- value
- 62.8
- group Id
- BG002
- spread
- 10.05
- value
- 63.2
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 484
- group Id
- BG001
- value
- 242
- group Id
- BG002
- value
- 726
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 406
- group Id
- BG001
- value
- 213
- group Id
- BG002
- value
- 619
- title
- Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 45
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 63
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 6
- title
- Native American
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 5
- title
- Black
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 13
- title
- Other
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 20
- title
- Unkown
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 484
- group Id
- BG001
- value
- 242
- group Id
- BG002
- value
- 726
- units
- Participants
- groups
- description
- Ribociclib was administered orally at a daily dose of 600mg for 21 consecutive days within a 28-day cycle. This treatment was combined with fulvestrant, which was administered via intramuscular injections of 500mg every 28 days starting on Day 1 of each cycle. Additionally, an extra dose of fulvestrant was given on Day 15 of Cycle 1.
- id
- BG000
- title
- Ribociclib + Fulvestrant
- description
- Placebo was administered orally for 21 consecutive days within a 28-day cycle. This treatment was combined with fulvestrant, which was administered via intramuscular injections of 500mg every 28 days starting on Day 1 of each cycle. Additionally, an extra dose of fulvestrant was given on Day 15 of Cycle 1. Participants were unblinded after the implementation of protocol amendment 4 (29-Jan-20) and were given the option to crossover to treatment with ribociclib and fulvestrant.
- id
- BG001
- title
- Placebo + Fulvestrant
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.78
- value
- 63.4
- group Id
- BG001
- spread
- 10.59
- value
- 62.8
- group Id
- BG002
- spread
- 10.05
- value
- 63.2
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 484
- group Id
- BG001
- value
- 242
- group Id
- BG002
- value
- 726
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 406
- group Id
- BG001
- value
- 213
- group Id
- BG002
- value
- 619
- title
- Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 45
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 63
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 6
- title
- Native American
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 5
- title
- Black
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 13
- title
- Other
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 20
- title
- Unkown
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle